Synairgen is a specialist respiratory biotech company whose primary focus is developing its investigative inhaled IFN-β candidate for the treatment of severe viral lung infections as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Founded by University of Southampton (UK) Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information, please visit www.synairgen.com.
View Top Employees from Synairgen Research LtdWebsite | http://www.synairgen.com |
Ticker | SNG |
Revenue | $4 million |
Funding | $12.5 million |
Employees | 24 (24 on RocketReach) |
Founded | 2003 |
Phone | +44 23 8051 2800 |
Fax | +44 23 8051 2800 |
Technologies |
JavaScript,
HTML,
Twitter
+12 more
(view full list)
|
Industry | Business Services, Biotechnology, Manufacturing, Pharmaceutical, Health Care |
Web Rank | 29 Million |
Competitors | Axsome Therapeutics, Inc., Hua Medicine, Karus Therapeutics Limited, NewBiotics, Verona Pharma |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 325 Companies, NAICS Code 325413 Companies, NAICS Code 3254 Companies |
Looking for a particular Synairgen Research Ltd employee's phone or email?
The Synairgen Research Ltd annual revenue was $4 million in 2024.
Richard Hennings is the Chief Commercial Officer of Synairgen Research Ltd.
24 people are employed at Synairgen Research Ltd.
The NAICS codes for Synairgen Research Ltd are [5417, 54171, 54, 32541, 32, 541714, 541, 325, 325413, 3254].
The SIC codes for Synairgen Research Ltd are [87, 873].